Shigellosis Clinical Trial
Official title:
Safety and Tolerability of a Candidate Bioconjugate Vaccine Against Shigella Flexneri 2a When Administered to Adult Volunteers
Verified date | December 2015 |
Source | LimmaTech Biologics AG |
Contact | n/a |
Is FDA regulated | No |
Health authority | United States: Food and Drug Administration |
Study type | Interventional |
This is a phase I, single-blind, randomized, placebo-controlled, single-center study in
healthy subjects using a staggered approach to dosing.
30 subjects will be randomized to receive 10 μg Flexyn2a candidate vaccine with or without
adjuvant or placebo.
Status | Completed |
Enrollment | 30 |
Est. completion date | September 2015 |
Est. primary completion date | May 2015 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | Both |
Age group | 18 Years to 50 Years |
Eligibility |
Inclusion Criteria: 1. Healthy male or female volunteers, age of 18 to 50 years (inclusive) at the time of enrollment. 2. Signed informed consent form. 3. Completion and review of comprehension test (achieved >70% accuracy) 4. Available for the required follow-up period and scheduled clinic visits. 5. Women: negative pregnancy test with understanding (through informed consent process) to not become pregnant or or breastfeed during the study or within twelve (12) weeks after the last vaccine dose. Exclusion Criteria: 1. Health condition that, in the opinion of the investigator, may interfere with optimal participation in the study or place the volunteer at increased risk of adverse Events (AEs). Study clinicians, in consultation with the PI, will use clinical judgment on a case by-case basis to assess safety risks under this criterion. The PI will consult with the Research Monitor as appropriate. 2. Clinically significant abnormalities on physical examination. 3. Clinically significant abnormalities on basic laboratory screening. 4. Presence of significant unexplained laboratory abnormalities that, in the opinion of the PI, may potentially confound the analysis of the study results 5. Regular use of constipation, antacid or anti-diarrheal medications or treatments. 6. Abnormal stool pattern (fewer than 3 stools per week or more than 3 per day) or loose/liquid stools more than occasionally. 7. Use of immunosuppressive drugs such as corticosteroids or chemotherapeutics that may influence antibody development. 8. Women currently nursing. 9. Participation in research involving another investigational product (defined as receipt of investigational product or exposure to invasive investigational device) within 30 days of planned date of first vaccination or anytime throughout the duration of the study. 10. Positive blood test for HBsAg, hepatitis C Virus (HCV), HIV-1. 11. Positive blood test for HLA-B27. 12. Immunosuppressive illness or immunoglobulin deficiency (serum immunoglobulin A level < 7 mg/dL or limit of detection of assay). 13. Family history of congenital or hereditary immunodeficiency. 14. Treatment with immunoglobulins or blood products within 3 months from first candidate vaccine injection. 15. History of microbiologically confirmed Shigella infection. 16. Personal or family history of inflammatory arthritis. 17. Personal or family history of irritable bowel syndrome. 18. Received previous experimental Shigella vaccine or live Shigella challenge. 19. Have had diarrhea while traveling outside the United States or lived for 2 or more months during the past 3 years in a country with potentially higher Shigella infection rates, including Africa, South America, Central America, and Asia (except Japan). 20. Occupation involving handling of Shigella bacteria currently, or in the past 3 years. 21. History of allergy to any vaccine. 22. History of allergy to aluminum hydroxide. 23. Serum immunoglobulin G endpoint titer = 2500 to Shigella Lipopolysaccharide. |
Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention
Country | Name | City | State |
---|---|---|---|
United States | WRAIR Clinical Trial Center (CTC) | Silver Spring | Maryland |
Lead Sponsor | Collaborator |
---|---|
LimmaTech Biologics AG | Naval Medical Research Center, Wellcome Trust |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Occurrence and severity of adverse events | Number and severity of local site injection and general adverse events will be collected and compared between the different arms of the study | until Day 56 | Yes |
Secondary | Evaluation of antigen-specific antibodies between baseline (D0) and after injection for all groups. | Immunogenicity will be evaluated after the first and second injection and compared to pre-immune levels | until Day 56 | No |
Secondary | Evaluation of antigen-specific antibodies between subjects receiving the candidate vaccine with and without adjuvant | Immunogenicity will be compared between subjects receiving candidate vaccine with and without adjuvant after the first and second injection | until Day 56 | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02797236 -
SF2a-TT15 Conjugate Vaccine in Healthy Adult Volunteers
|
Phase 1 | |
Completed |
NCT04056117 -
A Study to Determine If a New Shigella Vaccine is Safe, Induces Immunity and The Best Dose Among Kenyan Infants
|
Phase 1/Phase 2 | |
Not yet recruiting |
NCT05959616 -
Shigella Sonnei 53G Human Infection Study in Kenyan Adults
|
Phase 1 | |
Completed |
NCT02445963 -
Safety and Immunogenicity of Artificial Invaplex (Shigella Flexneri 2a InvaplexAR)
|
Phase 1 | |
Not yet recruiting |
NCT05961059 -
InvaplexAR-Detox and dmLT Adjuvant in the Netherlands and Zambia
|
Phase 1 | |
Completed |
NCT00485134 -
Shigella Flexneri 2a Invaplex 50 Vaccine Dose Finding and Assessment of Protection
|
Phase 1/Phase 2 | |
Completed |
NCT01369927 -
Shigella Sonnel O-SPC/rBRU Conjugate Vaccine
|
Phase 1 | |
Completed |
NCT02034500 -
Evaluate a New Shigella Sonnei Vaccine Administered Either by Intradermal, Intranasal or Intramuscular Route in Healthy Adults
|
Phase 1 | |
Completed |
NCT01509846 -
Safety Study of Inactivated Shigella Whole Cell Vaccine in Adults
|
Phase 1 | |
Completed |
NCT02105714 -
Diagnosis of Neglected Tropical Diseases Among Patients With Persistent Digestive Disorders
|
N/A | |
Withdrawn |
NCT01399424 -
Shigella Sonnei OSPC-rDT Conjugate Vaccine
|
Phase 1 | |
Completed |
NCT00800930 -
Therapeutic Induction of Endogenous Antibiotics
|
Phase 2 | |
Completed |
NCT00368316 -
Safety, Immunogenicity and Efficacy of Shigella Conjugate Vaccines in 1-4 Year Olds in Israel
|
Phase 3 | |
Recruiting |
NCT05182749 -
Safety and Efficacy of the Bacteriophage Preparation, ShigActive™, in a Human Experimental Model of Shigellosis
|
Phase 1/Phase 2 | |
Completed |
NCT02017899 -
A Phase 1, Dose Escalation Study, to Evaluate a New Shigella Sonnei Vaccine in Healthy Adults.
|
Phase 1 | |
Completed |
NCT01069471 -
Safety and Reactogenicity of Bioconjugate Vaccine to Prevent Shigella
|
Phase 1 | |
Completed |
NCT02646371 -
Phase 2b Challenge Study With the Bioconjugate Vaccine Flexyn2a
|
Phase 2 | |
Recruiting |
NCT05156528 -
Efficacy, Immunogenicity and Safety of S. Flexneriza-S. Sonnei Bivalent Conjugate Vaccine in Volunteers Aged From 6 Months to 5 Years
|
Phase 3 | |
Completed |
NCT03854929 -
Ciprofloxacin Versus Azithromycin for Children Hospitalised With Dysentery
|
Phase 4 | |
Recruiting |
NCT05121974 -
Tebipenem Trial in Children With Shigellosis
|
Phase 2 |